Here is another quick post.
I took a substantial position in the past month in Corvel Corp (Nasdaq: CRVL). Now that it’s rocketed up, I can write about it. Corvel’s domain is primarily in the software processing of workers’ compensation, insurance and related claims processing. They are vertically integrated to the extent that they provide the software and management systems.
I have been tracking this company for nearly 20 years, and owned and sold it over a decade ago, but I’ve been keeping an eye on it ever since (which assists the due diligence effort since there is such a long institutional history in my own mind). I finally had my opportunity.
It is a very unusually managed company. The pioneering manager (Gordon Clemons) still owns 9.4% of the company and sells bits and pieces now and then. He came on board 1988. The pioneering shareholder, Jeffrey Michael, owns 37% of the company through a holding company, and this was from 1990. They have since passed the baton to the next round of management, which does provide some succession risk (what happens to those shares?). Both Clemons and Michael have kept very low profile, along with current management. Almost nobody has heard of this company despite them doing over half a billion in revenues a year. They inhabit a niche that has very high barriers to entry. Their capital allocation strategy has also been relatively unusual – the underlying business makes a lot of free cash flow (after R&D) and all of that capital (up to the end of 2019, approximately $514 million) has gone into the repurchase of shares. They do not employ debt – indeed, not only did they not use their credit facility but they got rid of it in September 2019.
Their capital allocation strategy is uncommon. They maintain a cash float, and reinvest the rest of the proceeds in their own stock. As long as you assume the company will continue making money at the rate they are doing, these buybacks are extremely value-added over time. This makes past stock charts less comparable to present day situations. As of December 31, 2019, they have bought back nearly 2/3rds of their shares outstanding, at an average of US$14.25/share.
CRVL’s sensitivity to Covid-19 was primarily related to raw employment figures – their revenues are ultimately derived from employment and insurance factors. Their fiscal year end is in March and they released the annual results, which were in-line. The April to June quarter will show a slowdown, but after that, things should normalize.
While revenues will take a minor hit during COVID-19, as employment normalizes (in whatever form), Corvel will achieve its track record in annuity-like income and will be priced at a higher multiple than it was during COVID-19, which needless to say was lower than its ambient norm.
The company maintains a significant competitive advantage. Their pricing power will not erode too much as a result of the economic turmoil.
Needless to say, this is one trade I wish I made larger. My investment style is far too cautious at times.